Today: 2 July 2026
Browse Category

NYSE:PFE 20 January 2026 - 4 February 2026

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

New York, Jan 31, 2026, 13:49 EST — Market closed. Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
31 January 2026
······
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

New York, January 28, 2026, 11:16 a.m. ET — Regular session Pfizer shares were down 1.7% at $26.06 in late morning trade on Wednesday after the U.S. Centers for Medicare & Medicaid Services added its arthritis drug Xeljanz to the next round of Medicare drug price negotiations. CMS said the talks will run in 2026, with negotiated prices slated to take effect on Jan. 1, 2028, and companies facing a Feb. 28 deadline to sign participation agreements.
28 January 2026
···
Pfizer stock rises after Medicare flags Xeljanz for 2028 price talks — what investors watch next

Pfizer stock rises after Medicare flags Xeljanz for 2028 price talks — what investors watch next

New York, Jan 27, 2026, 19:28 ET — After-hours Pfizer’s stock jumped 2.3% to $26.50 in after-hours trading Tuesday. The boost follows the U.S. Centers for Medicare & Medicaid Services picking Pfizer’s arthritis drug Xeljanz for its upcoming Medicare drug price negotiations. Alongside Xeljanz, CMS included Gilead’s Biktarvy, AbbVie’s Botox, and Eli Lilly’s Trulicity. The agency said the 15 drugs chosen serve about 1.8 million Medicare patients and represent roughly $27 billion in Medicare drug spending.
28 January 2026
·
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

New York, January 27, 2026, 18:39 EST — After-hours Eli Lilly and Company shares ended Tuesday down $24.22, or roughly 2.3%, at $1,039.51. In after-hours trading, the stock edged up about 0.3% to $1,042.50. The U.S. Centers for Medicare & Medicaid Services announced it selected Lilly’s Trulicity, a type 2 diabetes drug, along with 14 other medicines for 2028 price negotiations. This marks the first time the list includes some therapies covered under Medicare Part B. Last year, the agency projected that negotiated prices for the 15 drugs chosen for 2027 would cut annual spending by 36%, roughly $8.5 billion, compared to recent costs.
28 January 2026
·······
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

New York, January 23, 2026, 14:26 EST — Regular session Pfizer shares dropped roughly 1.9% to $25.62 Friday afternoon, underperforming the health-care sector as the stock went ex-dividend. The Health Care Select Sector SPDR Fund dipped about 0.5%, while the SPDR S&P 500 ETF Trust inched up around 0.1%. Merck slipped about 1%, and Moderna tumbled over 7%. Trading volume for Pfizer hit roughly 24.8 million shares.
23 January 2026
·····
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

New York, January 20, 2026, 14:46 EST — During the regular session Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.
20 January 2026
···
1 2 3 4 5 … 11

Stock Market Today

  • Market profit-taking in focus as Najarian talks second-half winners and trends
    July 1, 2026, 6:52 PM EDT. Jon Najarian, co-founder of Market Rebellion, talks about market profit-taking and where the second-half stock market race could head. He flags data center stocks and points to Meta Platforms and its new cloud push, which sells extra artificial intelligence (A.I.) computing capacity. Najarian makes his case for fresh picks as investors look at their portfolios in a market that's shifting.
Go toTop